Abstract
150 mg/dL). Treatment groups were compared by ANCOVA. Results: Mean age was 62 years; the cohort was 58% male, and 91% had CHD or CHD risk-equivalents. The HDL-C increase observed with all 3 statins was greater among patients with low HDL-C or high TG or both, than among other patients (Table). Similarly, TG reduction with all 3 statins was greater among patients with low HDL-C or high TG or both, than among other patients. Percent increase in HDL-C and percent reduction in TG were nominally greater with RSV than with the other statins. LDL-C reduction did not differ between HDL-C or TG subgroups. Conclusions: Statins, particularly RSV, are more effective in raising HDL-C and lowering TG in patients who most need these benefits, that is, those with low HDL-C or high TG or both.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
